Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock is trading at $14.20, down -0.35%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TEVA shares have gain 2.08% over the last week, with a monthly amount glided 3.57%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, April 2024, New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024. In a post published today on Yahoo Finance, PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone microspheres (R064766).
From an analyst’s perspective:
Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on March 08, 2024, when JP Morgan upgraded its rating to a Neutral but kept the price target unchanged to $14 for it. Previously, Piper Sandler upgraded its rating to Overweight on February 12, 2024, and elevated its price target to $19. On January 23, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $14 on the stock. Piper Sandler upgraded its rating to a Neutral and increased its price target to $12 on January 03, 2024. HSBC Securities initiated its recommendation with a Buy and recommended $13 as its price target on December 18, 2023. UBS upgraded its rating to Buy for this stock on November 27, 2023, and upped its price target to $13. In a note dated July 06, 2023, UBS upgraded an Neutral rating on this stock and boosted its target price from $7 to $8.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock has fluctuated between $7.09 and $14.45 over the past year. Currently, Wall Street analysts expect the stock to reach $13.2 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $14.20 at the most recent close of the market. An investor can expect a potential drop of -7.04% based on the average TEVA price forecast.
Analyzing the TEVA fundamentals
Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] reported sales of 15.84B for the trailing twelve months, which represents a growth of 13.62%. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.08 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.09 points at the first support level, and at 13.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.39, and for the 2nd resistance point, it is at 14.58.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] reported earnings per share of $1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.77/share, meaning a difference of $0.23 and a surprise factor of 29.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.6 per share as compared to estimates of $0.61 per share, a difference of -$0.01 representing a surprise of -1.60%.
Ratios To Look Out For
For context, Teva- Pharmaceutical Industries Ltd. ADR’s Current Ratio is 1.02. Further, the Quick Ratio stands at 0.69, while the Cash Ratio is 0.26. Considering the valuation of this stock, the price to sales ratio is 1.00, the price to book ratio is 2.12.
Transactions by insiders
Recent insider trading involved Kalif Eliyahu Sharon, EVP, Chief Financial Officer, that happened on Mar 06 ’24 when 77550.0 shares were sold. EVP, International Markets, Sabag Mark completed a deal on Mar 05 ’24 to sell 100000.0 shares. Meanwhile, Exec. VP, European Commercial Daniell Richard sold 48629.0 shares on Mar 05 ’24.
